Our observations with the Tat-Cav3.2-III-IV peptide thus suggest that targeting Cav3.2 deubiquitination by USP5 is a potential new target for therapeutic approaches to pain hypersensitivity in diabetes and pain conditions associated with inflammatory disorders of the gut. This evidence concerns the gene USP5 and diabetes mellitus.